Clinical Trial Results: Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery [Phase 2]

View source ↗

Summary

Phase 2 randomized, controlled trial evaluating extended-release niacin (Niaspan) as an adjunct to recovery after ischemic stroke; study terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Niaspan (niacin (nicotinic acid))

Snippet

Sponsor: Henry Ford Health System | Conditions: Ischemic Stroke | Phase 2 | Status: TERMINATED | Results posted: 2026-08-28